Are Peptides Legal in Colorado? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Colorado as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Colorado attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Colorado statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. Colorado does go further on at least one compound: Human growth hormone and hCG (treated as anabolic steroids, Schedule III) (details below). Colorado also lists human growth hormone in its own controlled-substance law, on top of the federal rule. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Colorado at a glance

State controlled-substances law: Colo. Rev. Stat. § 18-18-101 et seq. (Uniform Controlled Substances Act of 2013); Schedule III at § 18-18-205 (codes.findlaw.com)
Human growth hormone under state law: Listed as a controlled substance in state law (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)
Research peptides scheduled by the state: Human growth hormone and hCG (treated as anabolic steroids, Schedule III) (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)
Board of Pharmacy on compounded GLP-1s: No statement located
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. C.R.S. § 12-240-107(1)(g) places telemedicine within the practice of medicine with no statutory in-person examination requirement. Colorado Medical Board policy holds telehealth to the in-person standard, requires Colorado licensure where the patient is located, and treats prescribing solely on an online questionnaire as unacceptable. (codes.findlaw.com)
State-level enforcement, 2023 to 2026: None found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Colorado, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Colorado:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Colorado. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Colorado law adds

Colorado's controlled-substances law (Colo. Rev. Stat. § 18-18-101 et seq. (Uniform Controlled Substances Act of 2013); Schedule III at § 18-18-205) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

Compounds Colorado has scheduled or restricted

Human growth hormone and hCG (treated as anabolic steroids, Schedule III) (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)

Human growth hormone

Colorado's definition of anabolic steroids expressly includes human chorionic gonadotropin and human growth hormone, and anabolic steroids are Schedule III, so unprescribed possession of HGH is a state controlled-substance offence as well as a federal one. (C.R.S. § 18-18-102(3)(a)(X) and (XI); § 18-18-205(2)(e)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

No Colorado Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Colorado pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Colorado medical board guidance specific to peptide therapy was located. A Colorado prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Colorado

No Colorado provision on unscheduled research peptides was found, but human growth hormone and hCG are Schedule III in Colorado, so unprescribed possession of those is a state controlled-substance offence. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Colorado is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. C.R.S. § 12-240-107(1)(g) places telemedicine within the practice of medicine with no statutory in-person examination requirement. Colorado Medical Board policy holds telehealth to the in-person standard, requires Colorado licensure where the patient is located, and treats prescribing solely on an online questionnaire as unacceptable. (codes.findlaw.com) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Colorado law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Colorado

The Bureau found no Colorado-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. SB 26-066, Regulation of Compounded Weight-Loss Medication (labelling, sourcing and per-dose fines), passed the Senate but was postponed indefinitely by the House health committee on 5 May 2026, so it is not law.

Frequently asked questions

Is BPC-157 legal in Colorado?

Colorado has not scheduled BPC-157, so possessing it is not a Colorado offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Colorado?

Yes. C.R.S. § 12-240-107(1)(g) places telemedicine within the practice of medicine with no statutory in-person examination requirement. Colorado Medical Board policy holds telehealth to the in-person standard, requires Colorado licensure where the patient is located, and treats prescribing solely on an online questionnaire as unacceptable. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Colorado?

Only with a valid prescription. Colorado lists human growth hormone as a controlled substance and federal law, 21 U.S.C. section 333(e), separately makes distribution or possession for a non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Colorado fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.